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OBJECTIVES: To assess the clinical and economic burden of gastroesophageal 
reflux disease (GERD) in the U.S. veteran population. METHODS: Patients 
diagnosed with GERD (International Classification of Diseases, Ninth Revision, 
Clinical Modification [ICD-9-CM] codes: 309.81, 530.1, 530.10-530.12, 530.81, 787.1) 
were included in a retrospective study (1/1/2006-5/31/2012) conducted using the 
Veterans Health Administration (VHA) Medical SAS Datasets. Continuous 
medical and pharmacy benefits were required 12-month pre- and 12-month 
post-index date (initial GERD diagnosis date). Comorbidities were examined for 
the 12 months baseline period; medication and treatment were examined during 
the 60-day follow-up period. Health care resource utilization and costs were 
assessed for the 12-month follow-up period. Descriptive statistics were 
calculated as means±standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: A total of 
1,123,133 GERD patients were identified in the database. During the 12-month 
baseline period, the most common comorbidities were unspecified essential 
hypertension (23.92%), diabetes (13.70%) and hyperlipidemia (8.36%). During the 
60 days post-index date, the most commonly prescribed medications were 
omeprazole (39.87%), simvastatin (27.52%), lisinopril (19.11%), ranitidine 
hydrochloride (12.48%), and hydrochlorothiazide (10.30%). During the 12-month 
follow-up period, percentages of inpatient (16.40%), emergency room (ER) 
(20.66%), physician office (99.83%), and outpatient visits (99.86%) were also 
calculated. Patient expenditures were found to be $5,498 (SD=$32,411) for 
inpatient, $246 (SD=$899) for ER, $6,724 (SD=$10,694) for physician office and 
$7,201 (SD=$11,407) for outpatient visits. CONCLUSIONS: Results suggest that 
omeprazole is the most frequently prescribed medication after a GERD diagnosis. 
GERD was associated with a high inpatient admission and ER visit rates, which 
translated into a significant cost burden for the health care system.  
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OBJECTIVES: To evaluate total annual all-cause costs of chronic constipation 
(CC) among patients with different health plan benefit designs and assess 
incremental costs of CC in a commercially insured population. METHODS: 
Patients were identified from the HealthCore Integrated Research Database as 
follows: (1) age ≥18 years as of January 1, 2010; (2) continuous eligibility in 2010; 
(3) ≥2 constipation diagnoses (ICD-9-CM: 564.0x) occurring ≥90 days apart or ≥1 
constipation diagnosis plus ≥1 constipation-related prescription occurring ≥90 
days apart. A control group without irritable bowel syndrome, constipation, 
abdominal pain, or bloating was randomly selected using 1:1 matching on basic 
demographic characteristics. Patients were categorized by health plan benefit 
design into non-capitated health maintenance organizations (HMO), preferred 
provider organizations (PPO), Medicare Advantage (MA), and other benefit 
designs. Total all-cause health care costs included pharmacy costs and costs 
from medical services. Generalized linear models were used to evaluate the 
incremental costs attributable to CC. RESULTS: Of 14,854 CC patients and 
controls identified, 71.7% had PPO, 12.0% had non-capitated HMO, 10.2% had MA, 
and 6.1% had other benefit designs. Mean age (±SD) was 58.7 (±20.4) years; 75.4% 
were female. Overall, CC patients had $8,713 (P<0.001) higher unadjusted total 
annual all-cause health care costs versus matched controls; costs were $9,736 
(P<0.001) higher for non-capitated HMO, $8,029 (P<0.001) for PPO, and $11,813 
(P<0.001) for MA. Medical costs were the primary driver of unadjusted all-cause 
costs regardless of benefit design (82%-84% of total costs). This finding remained 
consistent in the overall study population even after adjusting for demographics 
and comorbidities. Total incremental all-cause costs associated with CC were 
$3,508 (P<0.001), with 81% for medical services. CONCLUSIONS: The economic 
burden of CC is substantial in a US commercially insured population. A 
consistent burden was seen across different health plan benefit designs, with 
costs driven by the use of medical services.  
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OBJECTIVES: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that 
results from chronic inflammation restricted to all or part of the colon and 
begins in the rectum. UC significantly impact quality of life and accounts for 
substantial costs to the health care system and society. The objective of this 
study was to describe and estimate health care resource utilization in the 
treatment of UC from a health care system perspective. METHODS: A 
retrospective study of the Quebec provincial drug reimbursement program 
(RAMQ) was conducted using a randomly selected group of patients who 
received at least one diagnosis of UC (ICD-9=556.x) between January 1st, 2010 and 
December 31st, 2011, but who did not received a diagnosis of Crohn’s disease 
(ICD-9=555.x). A control group of patients without any diagnosis of UC was 
created on a 1:1 ratio and matched for age and gender. The difference between 
the costs of resources consumed during the 2year study period by the two groups 
(using t-test) provided an estimate of the incremental cost associated with the 
management of UC. RESULTS: A total of 2,975 patients with UC were included in 
the study (mean age=55.5 years, 52% females). During the 2-year study period, 
patients had received a total of 57,264 scripts for anti-inflammatory drugs, 
immunosuppressors and/or anti-TNFα agents. The total cost of medical 
procedures, medications and hospitalizations were higher for UC patients, with 
an annual incremental cost per patient of CAN$370 (95%CI: 331-410), CAN$2,374 
(95%CI: 2135-2613) and CAN$2,795 (95%CI: 2399-3192), respectively. The annual 
difference in direct costs between UC patients and controls was estimated at 
CAN$5,539 (95%CI: 5,036-6,043) per patient. CONCLUSIONS: The present analysis 
illustrates the high cost of treatments, the high frequency of hospitalizations 
resulting in increased hospitalization costs and the substantial economic 
burden, in terms of direct medical costs associated with UC.  
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OBJECTIVES: Antiemetic is a drug that is effective against vomiting and nausea. 
The objective of this study is to calculate price trends for individual antiemetic 
and to describe the trends of utilization and spending on antiemetic drugs in the 
U.S. Medicaid program. METHODS: A retrospective descriptive analysis was 
performed using data from the Medicaid database from 1991 through second 
quarter 2011. We extracted the utilization and expenditure data from the 
national Medicaid pharmacy files collected by the Centers for Medicare & 
Medicaid Services. Study drugs include antihistamines (cyclizine, 
dimenhydrinate, buclizine), steroids (dexamethasone, methylprednisolone), 
dopamine antagonists (droperidol, ondansetron, granisetron, palonosetron). 
Total prescriptions reimbursed by Medicaid and total reimbursement cost were 
calculated by adding the data for each antiemetic identified by its NDC. The 
Annual totals of reimbursement per-prescription were calculated as annual total 
reimbursement divided by Annual total number of prescriptions. RESULTS: The 
total number of prescriptions which paid by Medicaid was increased from 
$339,822 in 1991 to $1.0 million in second quarter of 2011. The data shows 80% 
decrease in antiemetic utilization in 1999. The drug Ondansetron has increasing 
trends after 2006 up to about 70% in the first quarter of 2011. The price was in 
increasing rate until 2011. About 100% increase in the price of generic Zofran. 
The average of reimbursement per prescription has increased from $15.22 in 
1991 to $36.90 in 2011. CONCLUSIONS: In the light of this study, more studies are 
needed to create antiemetic guidelines that would help to improve efficacy, 
increase the patients compliance, and decrease the antiemetic costs.  
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OBJECTIVES: To evaluate the cost-effectiveness of linaclotide 290 mcg once daily 
versus lubiprostone 8 mcg twice daily in the treatment of adult patients with 
irritable bowel syndrome with constipation (IBS-C) METHODS: Using model 
inputs derived from published literature, linaclotide Phase III trial data, and a 
physician survey on resource utilization associated with treatment failure, a 
decision-tree model was constructed to estimate outcomes and costs of 
treatment for IBS-C. Response to therapy was defined as (1) a ≥14-point increase 
from baseline in IBS-QOL overall score at Week 12 or (2) one of the top two 
responses (moderately/significantly relieved) on a seven-point IBS symptom 
relief question in ≥2 of 3 months. Patients who do not respond to therapy are 
assumed to fail therapy and accrue costs associated with a treatment failure. 
Model time horizon is aligned with clinical trial duration at 12 weeks. Model 
outputs include number of responders, quality-adjusted life-years (QALYs), total 
costs (including direct and indirect), and incremental cost-effectiveness ratios 
(ICERs). Both one-way and probabilistic sensitivity analyses were conducted. 
RESULTS: Treatment for IBS-C with linaclotide produced more responders than 
lubiprostone for both response definitions (19.3% vs. 13.0% and 61.6% vs. 57.2% 
for IBS-QOL and symptom relief, respectively), lower per-patient costs ($780 vs. 
$870 and $1,014 vs. $1,088), and higher QALYs (0.1924 vs. 0.1917 and 0.1909 vs. 
0.1894, over the 12-week time horizon). Therefore, linaclotide was dominant 
(more effective and less expensive) compared to lubiprostone. Results were 
similar to base-case for most one-way sensitivity analyses. The majority of 1,000 
second order Monte Carlo simulations resulted in linaclotide dominant ICERs for 
both definitions of treatment response. CONCLUSIONS: Linaclotide was found to 
be cost-effective versus lubiprostone for treatment of adult patients with IBS-C.  
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OBJECTIVES: To assess the cost-effectiveness of infliximab as induction therapy 
(3 doses) for the treatment of severe active ulcerative colitis, i.e. exacerbations 
requiring hospitalization in adult patients with an inadequate response to 
conventional therapy including intravenous glucocorticoids, compared with 
surgery (colectomy) in Poland. METHODS: This study used the decision tree 
model which was positively received by NICE and adjusted to Polish settings. 
